📊 GERN Key Takeaways
Is Geron Corp. (GERN) a Good Investment?
Geron is a pre-profitability biopharmaceutical company with severe cash burn of $111M annually against limited revenue of $135.9M, indicating an unsustainable business model. The company is losing $0.61 on every dollar of revenue with negative operating margins of -50.5% and deteriorating free cash flow. While improved net income YoY suggests progress, the fundamental cash burn rate and inability to generate positive operating income present significant going concern risks without successful commercialization.
Geron shows meaningful revenue generation and improved net loss versus the prior year, but the business remains deeply unprofitable with negative operating income, negative free cash flow, and weak interest coverage. Balance sheet liquidity ratios are currently solid, yet the combination of $77.56M in cash and $111.72M in annual free cash flow burn raises concern about funding durability and the quality of growth unless margins improve quickly.
Why Buy Geron Corp. Stock? GERN Key Strengths
- Strong liquidity position with $77.6M cash and 4.66x current ratio providing runway for operations
- YoY improvement in net loss by 52.2% indicating operational progress toward profitability
- Low debt-to-equity ratio of 0.53x with manageable leverage for balance sheet stability
- Revenue has scaled to $135.87M, indicating commercial traction rather than a purely pre-revenue profile
- Net loss and diluted EPS improved materially year over year, suggesting operating progress
- Liquidity appears solid on the surface with a 4.66x current ratio and 3.62x quick ratio
GERN Stock Risks: Geron Corp. Investment Risks
- Severe annual cash burn of $111M unsustainable without revenue growth or capital raises
- Negative free cash flow of -$111.7M and -82.2% FCF margin indicates cash depletion trajectory
- Operating losses of -$68.6M with -50.5% operating margin shows core business unable to sustain operations
- Limited revenue base of $135.9M insufficient to cover negative $111M operating cash flow
- Pharmaceutical sector execution risk with uncertain drug commercialization timelines
- Profitability remains very weak, with -50.5% operating margin and -61.5% net margin
- Cash generation is poor, with operating cash flow of -$111.04M and free cash flow of -$111.72M
- Negative interest coverage and $119.55M of long-term debt increase financing and balance sheet risk if losses persist
Key Metrics to Watch
- Quarterly operating cash flow trend and cash runway duration at current burn rate
- Revenue growth rate and gross margins upon drug commercialization
- Quarterly operating loss reduction trajectory toward breakeven
- Capital raise activities and dilution impact on existing shareholders
- Free cash flow burn relative to cash on hand
- Operating margin improvement as revenue scales
Geron Corp. (GERN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.66x current ratio provides a solid financial cushion.
GERN Profit Margin, ROE & Profitability Analysis
GERN vs Healthcare Sector: How Geron Corp. Compares
How Geron Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Geron Corp. Stock Overvalued? GERN Valuation Analysis 2026
Based on fundamental analysis, Geron Corp. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Geron Corp. Balance Sheet: GERN Debt, Cash & Liquidity
GERN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Geron Corp.'s revenue has grown significantly by 31% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.32 indicates the company is currently unprofitable.
GERN Revenue Growth, EPS Growth & YoY Performance
GERN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $28.3M | -$16.4M | $-0.03 |
| Q2 2025 | $882.0K | -$16.4M | $-0.02 |
| Q1 2025 | $304.0K | -$19.8M | $-0.03 |
| Q3 2024 | $164.0K | -$26.4M | $-0.04 |
| Q2 2024 | $29.0K | -$38.1M | $-0.09 |
| Q1 2024 | $21.0K | -$38.1M | $-0.07 |
| Q3 2023 | $164.0K | -$28.1M | $-0.08 |
| Q2 2023 | $29.0K | -$28.1M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Geron Corp. Dividends, Buybacks & Capital Allocation
GERN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Geron Corp. (CIK: 0000886744)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 14, 2026 | 4 | xslF345X06/form4-04152026_120410.xml | View → |
| Apr 7, 2026 | DEF 14A | gern-20260407.htm | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_040401.xml | View → |
| Mar 26, 2026 | 4 | xslF345X06/form4-03262026_090305.xml | View → |
| Mar 26, 2026 | 4 | xslF345X06/form4-03262026_090309.xml | View → |
❓ Frequently Asked Questions about GERN
What is the AI rating for GERN?
Geron Corp. (GERN) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GERN's key strengths?
Claude: Strong liquidity position with $77.6M cash and 4.66x current ratio providing runway for operations. YoY improvement in net loss by 52.2% indicating operational progress toward profitability. ChatGPT: Revenue has scaled to $135.87M, indicating commercial traction rather than a purely pre-revenue profile. Net loss and diluted EPS improved materially year over year, suggesting operating progress.
What are the risks of investing in GERN?
Claude: Severe annual cash burn of $111M unsustainable without revenue growth or capital raises. Negative free cash flow of -$111.7M and -82.2% FCF margin indicates cash depletion trajectory. ChatGPT: Profitability remains very weak, with -50.5% operating margin and -61.5% net margin. Cash generation is poor, with operating cash flow of -$111.04M and free cash flow of -$111.72M.
What is GERN's revenue and growth?
Geron Corp. reported revenue of $135.9M.
Does GERN pay dividends?
Geron Corp. does not currently pay dividends.
Where can I find GERN SEC filings?
Official SEC filings for Geron Corp. (CIK: 0000886744) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GERN's EPS?
Geron Corp. has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GERN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Geron Corp. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GERN stock overvalued or undervalued?
Valuation metrics for GERN: ROE of -37.0% (sector avg: 15%), net margin of -61.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GERN stock in 2026?
Our dual AI analysis gives Geron Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GERN's free cash flow?
Geron Corp.'s operating cash flow is $-111.0M, with capital expenditures of $680.0K. FCF margin is -82.2%.
How does GERN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -61.5% (avg: 12%), ROE -37.0% (avg: 15%), current ratio 4.66 (avg: 2).